 | Preface |
|
v | |
| List of Participants |
|
ix | |
| Nonalcoholic Fatty Liver (NAFL): Overview |
|
|
S.H. CALDWELL, A. AL-OSAIMI, C. CHANG, C. DAVIS, E.E. HESPENHEIDE, L. KRUGNER-HIGBY, A.I. HYLTON, J.C. IEZZONI, T.H. LE, R.K. NAKAMOTO, J.REDICK, and T. PETERSON |
|
|
1 | (43) |
| Role of Leptin in Pathogenesis of NASH |
|
|
K. IKEJIMA, T. LANG, S. YAMASHINA, N. ENOMOTO, Y. TAKEI, and N. SATO |
|
|
44 | (6) |
| Zone 3 Predominance of Histopathological Features in Nonalcoholic Steatohepatitis |
|
|
H. ENZAN, M. TOI, Y. HAYASHI, T. HAMAUZU, N. KURODA, and M. HIROI |
|
|
50 | (8) |
| Genetic Background of Japanese Patients with Nonalcoholic Steatohepatitis (NASH) |
|
|
T. SAIBARA, C. NAMIKAWA, Z. SHU-PING, M. RUI-HONG, Y. NOZAKI, Y. NEMOTO, M. ONO, N. AKISAWA, S. IWASAKI, M. HIROI, H. ENZAN, and S. ONISHI |
|
|
58 | (6) |
| Predictors of Nonalcoholic Steatohepatitis in Japanese Patients: Thioredoxin and NASH |
|
|
T. OKANOUE, N. YAMAUCHI, M. FURUTANI, A. HIROHAMA, Y. SUMIDA, and T. NAKASHIMA |
|
|
64 | (9) |
| Clinical Features of Patients with Nonalcoholic Fatty Liver Disease |
|
|
E. HASHIMOTO, H. KANEDA, Y. YOSHIOKA, M. TANIAI, K. TOKUSHIGE, and K. SHIRATORI |
|
|
73 | (11) |
| Pathogenesis and Significance of Restricted Diet and Exercise Therapy in Nonalcoholic Steatohepatitis (NASH) |
|
|
T. UENO, T. NAKAMURA, N. SASAKI, Y. MORITA, E. NAGATA, and M. SATA |
|
|
84 | (8) |
| Mammalian Target of Rapamycin (mTOR) |
|
|
|
|
92 | (8) |
| Effect of Oral Supplementation with Branched-Chain Amino Acids on Albumin Concentration in the Early Stage of Cirrhosis |
|
|
S. NISHIGUCHI, D. HABU, and S. SHIOMI |
|
|
100 | (8) |
| Nutritional Therapy in Patients with Liver Cirrhosis |
|
|
M. TSUCHIYA, I. SAKAIDA, M. OKAMOTO, and K. OKITA |
|
|
108 | (7) |
| Subject Index |
|
115 | |
|